NEW
YORK, Feb. 25, 2025 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that it has received written notification from the
Listings Qualifications Department of the Nasdaq Stock Market LLC
("Nasdaq") that the Company has regained compliance with the
minimum bid price requirement for continued listing on the Nasdaq
Capital Market.
As previously disclosed, the Company was notified by Nasdaq that
it was not in compliance with this listing rule because it failed
to maintain a minimum closing bid price of its common stock of
$1.00 per share for 30 consecutive
business days. To regain compliance, the Company was required to
maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive
trading days. This requirement was met on February 21, 2025.
The Company's common stock will continue to trade on the Nasdaq
Capital Market under the symbol "LUCD".
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company and
subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the
millions of patients with gastroesophageal reflux disease (GERD),
also known as chronic heartburn, who are at risk of developing
esophageal precancer and cancer. Lucid's EsoGuard®
Esophageal DNA Test, performed on samples collected in a brief,
noninvasive office procedure with its EsoCheck®
Esophageal Cell Collection Device, represent the first and only
commercially available tools designed with the goal of preventing
cancer and cancer deaths through widespread, early detection of
esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302384434.html
SOURCE Lucid Diagnostics
